Trial reportEuropean journal of medical research2009
A phase II study on safety and efficacy of high-dose N-acetylcysteine in patients with cystic fibrosis.
Trial report in European journal of medical research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis.The Cochrane database of systematic reviews · 2013Pooled it
- N-Acetylcysteine Rinse for Thick Secretion and Mucositis of Head and Neck Chemoradiotherapy (Alliance MC13C2): A Double-Blind Randomized Clinical Trial.Mayo Clinic proceedings · 2019Trial
- Mucoactive Agents in Muco-Obstructive Lung Diseases: A Critical Reappraisal of Pharmacological Effects and Clinical Outcomes.Pharmaceuticals (Basel, Switzerland) · 2026Review
- N-acetylcysteine: evidence based consensus document on the therapeutic advantages in respiratory diseases (NECTAR).Frontiers in medicine · 2026Review
- N-acetylcysteine Clinical Applications.Cureus · 2024Review
- N-Acetylcysteine and Its Immunomodulatory Properties in Humans and Domesticated Animals.Antioxidants (Basel, Switzerland) · 2023Review
- Advances in the Use ofAntioxidants (Basel, Switzerland) · 2023Review
- N-acetylcysteine (NAC) and Its Role in Clinical Practice Management of Cystic Fibrosis (CF): A Review.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Current and Emerging Therapies to Combat Cystic Fibrosis Lung Infections.Microorganisms · 2021Review
- Novel Antioxidant Therapy with the Immediate Precursor to Glutathione, γ-Glutamylcysteine (GGC), Ameliorates LPS-Induced Cellular Stress in In Vitro 3D-Differentiated Airway Model from Primary Cystic Fibrosis Human Bronchial Cells.Antioxidants (Basel, Switzerland) · 2020Article
- Article
- Antioxidant supplementation for lung disease in cystic fibrosis.The Cochrane database of systematic reviews · 2019Review
- Current and future treatment options for cystic fibrosis lung disease: latest evidence and clinical implications.Therapeutic advances in chronic disease · 2016Review
- The effect of dietary modulation of sulfur amino acids on cystathionine β synthase-deficient mice.Annals of the New York Academy of Sciences · 2016Review
- Redox balance in cystic fibrosis.The international journal of biochemistry & cell biology · 2014Review
- State of progress in treating cystic fibrosis respiratory disease.BMC medicine · 2012Review
- Article
- Article
- Metabolomic profiling reveals biochemical pathways and biomarkers associated with pathogenesis in cystic fibrosis cells.The Journal of biological chemistry · 2010Article
- Mucoactive drugs.European respiratory review : an official journal of the European Respiratory Society · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe conducted a single-centre, randomised, double-blinded, placebo-controlled phase II clinical study to test safety and efficacy of a 12-week therapy with low-dose (700 mg/daily) or high-dose (2800 mg/daily) of NAC.
methodsTwenty-one patients (DeltaF508 homo/heterozygous, FEV1>40% pred.) were included in the study. After a 3-weeks placebo run-in phase, 11 patients received low-dose NAC, and 10 patients received high-dose NAC. Outcomes included safety and clinical parameters, inflammatory (total leukocyte numbers, cell differentials, TNF-alpha, IL-8) measures in induced sputum, and concentrations of extracellular glutathione in induced sputum and blood.
resultsHigh-dose NAC was a well-tolerated and safe medication. High-dose NAC did not alter clinical or inflammatory parameters. However, extracellular glutathione in induced sputum tended to increase on high-dose NAC.
conclusionsHigh-dose NAC is a well-tolerated and safe medication for a prolonged therapy of patients with CF with a potential to increase extracellular glutathione in CF airways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.